Articles By Janet Pope, MD, MPH, FRCPC
CV risk factors not equal when considering magnitude of risk
What can we learn from Oral Surveillance? The Oral Surveillance trial has almost become a household word for rheumatologists.
Read ArticleAre TYK2 inhibitors ‘ticked’ to be part of the JAK family?
Are TYK2 inhibitors JAK inhibitors? Are they effective in PsA? Are they safer than JAKi? Read on to learn more.
Read ArticleBest of 2021: Perspectives on CV safety: JAKi (Tofacitinib) and TNF inhibitors
Safety comparisons of JAKi (tofacitinib) vs. TNFi from Oral Surveillance showed that, in patients with active RA on MTX and aged >50 years with one or more CV risk factors, that there was numerically more MACE events, malignancies, and VTE especially in higher dose.
Read ArticleTop vasculitis takeaways from ACR 2021
There were several hot topics at ACR21. Here I concentrate on top abstracts in vasculitis.
Read ArticlePerspectives on CV safety: JAK inhibitor (Tofacitinib) and TNF inhibitors
Safety comparisons of JAKi (tofacitinib) vs. TNFi from Oral Surveillance showed that, in patients with active RA on MTX and aged >50 years with one or more CV risk factors, that there was numerically more MACE events, malignancies, and VTE especially in higher dose.
Read ArticleRacial/ethnic disparity in U.S. lupus nephritis mortality
At #ACR21, the plenary session included an analysis of deaths from SLE throughout the US comparing 1999 to 2019 (Abstract #0454).
Read ArticleReader beware! Interpretation of effectiveness & safety of JAKi vs bDMARDs in real world data
Multiple studies compared effectiveness, retention and/or safety of biological DMARDs (bDMARDs) and JAK inhibitors (JAKi) at EULAR 2021.
Read ArticleLessons learned in SLE
An analysis of SLE samples from SLE 1760 patients with active disease from RCTs illustrated several known and some new targets for SLE treatment (POS0351).
Read ArticleHow are RA patients doing using telemedicine/virtual care?
Rheumatologists switched their practices overnight from primarily in person to nearly all virtual care as COVID-19 pandemic geared up in March 2020 and then to a blend of in person and virtual care. How are RA patients doing?
Read ArticleWhat’s new in knee osteoarthritis that matters?
Are intra-articular steroid injections effective in symptomatic knee OA? Do they accelerate cartilage loss? Does weight less actually help? Do we have DMARDs for knee OA? Insights from 2020 ACR Convergence.
Read Article